NCT01266993 - Persistence and Booster Study of GSK Biologicals' Meningococcal Vaccine (GSK134612) in Healthy Children | Biotech Hunter

Enrollment

271

Participants

Timeline

Start Date

January 3, 2011

Primary Completion Date

March 31, 2014

Study Completion Date

May 17, 2014

Conditions

Infections, MeningococcalMeningococcal Vaccines

Interventions

BIOLOGICAL

Nimenrix (GSK134612 vaccine)

Intramuscular, 1 dose

BIOLOGICAL

Menjugate

Intramuscular, 1 dose

Trial Locations (24)

10315

GSK Investigational Site, Berlin

10627

GSK Investigational Site, Berlin

13055

GSK Investigational Site, Berlin

14197

GSK Investigational Site, Berlin

32479

GSK Investigational Site, Hille

32756

GSK Investigational Site, Detmold

37000

GSK Investigational Site, Tours

42551

GSK Investigational Site, Velbert

42579

GSK Investigational Site, Heiligenhaus

42719

GSK Investigational Site, Solingen

47574

GSK Investigational Site, Goch

54290

GSK Investigational Site, Trier

55131

GSK Investigational Site, Mainz

67227

GSK Investigational Site, Frankenthal

67380

GSK Investigational Site, Lingolsheim

75015

GSK Investigational Site, Paris

76600

GSK Investigational Site, Le Havre

81241

GSK Investigational Site, Munich

81735

GSK Investigational Site, Munich

82140

GSK Investigational Site, Olching

83300

GSK Investigational Site, Draguignan

01700

GSK Investigational Site, Miribel

06300

GSK Investigational Site, Nice

06700

GSK Investigational Site, Saint-Laurent-du-Var